We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

80 hedge funds and large institutions have $206M invested in Tempest Therapeutics in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more capital invested

Capital invested by funds: $149M → $206M (+$56.9M)

35% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 17

6% less funds holding

Funds holding: 85 → 80 (-5)

35% less call options, than puts

Call options by funds: $160K | Put options by funds: $247K

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

Holders
80
Holders Change
-5
Holders Change %
-5.88%
% of All Funds
2.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
23
Reduced
17
Closed
14
Calls
$160K
Puts
$247K
Net Calls
-$87K
Net Calls Change
+$121K

Top Buyers

Rank Fund Capital Flow
1
PCM
Portolan Capital Management
Massachusetts
+$2.86M
2
Northern Trust
Northern Trust
Illinois
+$1.79M
3
Deutsche Bank
Deutsche Bank
Germany
+$1.18M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$778K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$633K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$2.3M
2
Marshall Wace
Marshall Wace
United Kingdom
-$1.47M
3
Invesco
Invesco
Georgia
-$961K
4
Jennison Associates
Jennison Associates
New York
-$760K
5
Millennium Management
Millennium Management
New York
-$712K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
76
BNP Paribas Financial Markets
France
$16.7K +$18.1K +1 New
MFS
77
MSI Financial Services
Massachusetts
$14K – – –
TCOV
78
Trust Company of Vermont
Vermont
$10K – – –
JP Morgan Chase
79
JP Morgan Chase
New York
$9K -$2.3M -127 Closed
Bank of Montreal
80
Bank of Montreal
Ontario, Canada
$7K – – –
PAM
81
Panagora Asset Management
Massachusetts
$7K – – –
Barclays
82
Barclays
United Kingdom
$4K – – –
Creative Planning
83
Creative Planning
Kansas
$3K – – –
Zurich Cantonal Bank
84
Zurich Cantonal Bank
Switzerland
$3K – – –
Royal Bank of Canada
85
Royal Bank of Canada
Ontario, Canada
$2K – – –
KF
86
Krilogy Financial
Missouri
$1K – – –
TRCT
87
Tower Research Capital (TRC)
New York
$1K – – –
TCIM
88
TIAA CREF Investment Management
New York
$681 – – –
VOYA Investment Management
89
VOYA Investment Management
Georgia
$111 – – –
Invesco
90
Invesco
Georgia
– -$961K -63 Closed
Millennium Management
91
Millennium Management
New York
– -$712K -47 Closed
FMA
92
FNY Managed Accounts
New York
– -$208K -14 Closed
TMC
93
Trellus Management Company
Florida
– -$208K -14 Closed
EA
94
Emerald Acquisition
Washington
– -$195K -13 Closed
ARTA
95
A.R.T. Advisors
New York
– -$176K -12 Closed
QSS
96
Quantitative Systematic Strategies
Florida
– -$164K -10 Closed
Citadel Advisors
97
Citadel Advisors
Florida
– -$122K -8 Closed
VKH
98
Virtu KCG Holdings
New York
– -$81K -5 Closed
WS
99
Wedbush Securities
California
– -$58K -4 Closed
BGIM
100
Brandywine Global Investment Management
Pennsylvania
– -$45K -3 Closed
1 2 3
4
5

TPST Hedge Fund Activity: Q3 2016 in Review

80 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2016, worth a combined $206M — up 38% from $149M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of TPST and 9 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 23 added.

The largest buyer was Portolan Capital Management, adding an estimated $2.86M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.3M sold.

  • 80 institutional investors held Tempest Therapeutics (TPST) as of Q3 2016, down from 85 in Q2 2016.
  • Funds reported $206M of Tempest Therapeutics stock for Q3 2016, up 38% quarter-over-quarter.
  • 9 funds opened new Tempest Therapeutics positions in Q3 2016 and 14 closed out, a net change of -5 holders.
  • The largest Tempest Therapeutics buyer in Q3 2016 was Portolan Capital Management, an estimated $2.86M added.
  • The largest Tempest Therapeutics seller in Q3 2016 was JP Morgan Chase, an estimated $2.3M sold.

Based on aggregated 13F filings for Q3 2016.